Related Experiment Video
Updated: Jul 19, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Hypertrophic Cardiomyopathy: A Cardiovascular Challenge Becoming a Contemporary Treatable Disease
Stefanos G Sakellaropoulos1, Benedict Schulte Steinberg2
1Department of Internal Medicine, Cardiology Clinic, Kantonsspital Baden, Baden, Switzerland.
Insights
Hypertrophic cardiomyopathy, a common genetic heart disease, requires comprehensive diagnostics and individualized therapy. Ongoing research aims to improve treatment outcomes for affected individuals, including young people and athletes.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary genetic myocardial disorder.
- It results from mutations in cardiac sarcomere protein genes.
- HCM is a leading cause of sudden cardiac death in young individuals and athletes.
Purpose of the Study:
- To review current diagnostic and therapeutic strategies for HCM.
- To highlight the need for individualized risk and therapy stratification.
- To discuss emerging diagnostic and therapeutic approaches for HCM.
Main Methods:
- Comprehensive review of diagnostic modalities including echocardiography, MRI, and genetic testing.
- Analysis of current therapeutic options and their limitations.
- Evaluation of novel diagnostic and therapeutic strategies in clinical trials.
Main Results:
- Diagnosis and risk stratification necessitate a multimodal approach.
- Current therapies like beta-blockers and verapamil have limitations and potential adverse effects.
- Emerging treatments show promise but require further investigation.
Conclusions:
- Personalized treatment based on phenotype and genotype is crucial for HCM management.
- Further robust clinical trials are essential for validating new therapies.
- Advancements in diagnostics and treatments offer hope for improved patient outcomes.
Abstract:
Hypertrophic cardiomyopathy is one of the most common genetic inherited diseases of myocardium, which is caused by mutation in genes encoding proteins for the cardiac sarcomere. It is the most frequent cause of sudden death in young people and trained athletes. All diagnostic methods, including heart catheterization, transthoracic and transesophageal echocardiography, magnetic resonance imaging, genetic counseling and tissue biopsy are required for risk and therapy stratification and should be individualized depending on phenotype and genotype. Current therapy has not been tested adequately. Beta-blockers and verapamil can cause hypotension which can make hypertrophic cardiomyopathy worse. Disopyramide has been inadequately studied, and mavacamten was only studied in small trials. More definitive trials are currently ongoing. Novel invasive and noninvasive diagnostics, medical therapies, interventional and surgical approaches tend to influence the natural history of the disease, favoring a better future for this patient population.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis III: Medical Management

